Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VIR logo VIR
Upturn stock ratingUpturn stock rating
VIR logo

Vir Biotechnology Inc (VIR)

Upturn stock ratingUpturn stock rating
$5.72
Last Close (24-hour delay)
Profit since last BUY1.6%
upturn advisory
Consider higher Upturn Star rating
BUY since 12 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/14/2025: VIR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $17.22

1 Year Target Price $17.22

Analysts Price Target For last 52 week
$17.22 Target price
52w Low $4.16
Current$5.72
52w High $14.45

Analysis of Past Performance

Type Stock
Historic Profit -72.65%
Avg. Invested days 25
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 794.60M USD
Price to earnings Ratio -
1Y Target Price 17.22
Price to earnings Ratio -
1Y Target Price 17.22
Volume (30-day avg) 9
Beta 1.27
52 Weeks Range 4.16 - 14.45
Updated Date 10/14/2025
52 Weeks Range 4.16 - 14.45
Updated Date 10/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.91

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -9768.45%

Management Effectiveness

Return on Assets (TTM) -24.73%
Return on Equity (TTM) -46.22%

Valuation

Trailing PE -
Forward PE 4.36
Enterprise Value 282477971
Price to Sales(TTM) 41.82
Enterprise Value 282477971
Price to Sales(TTM) 41.82
Enterprise Value to Revenue 19.63
Enterprise Value to EBITDA 0.9
Shares Outstanding 138916426
Shares Floating 95660629
Shares Outstanding 138916426
Shares Floating 95660629
Percent Insiders 10.47
Percent Institutions 81.21

ai summary icon Upturn AI SWOT

Vir Biotechnology Inc

stock logo

Company Overview

overview logo History and Background

Vir Biotechnology, Inc. was founded in 2016 with the mission to combat infectious diseases. It has focused on developing treatments for diseases like hepatitis B, influenza A, and COVID-19, leveraging its advanced technologies to identify and develop promising therapeutic candidates.

business area logo Core Business Areas

  • Infectious Disease Therapeutics: Focuses on developing treatments and preventative measures for a variety of infectious diseases, including viral diseases.
  • Antibody Discovery: Utilizes proprietary antibody discovery platforms to identify and develop monoclonal antibodies for therapeutic use.

leadership logo Leadership and Structure

The company has a leadership team of scientists and business professionals. The organizational structure is typical of a biotechnology firm, with research, development, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • Sotrovimab (Xevudy): A monoclonal antibody treatment for COVID-19, developed in partnership with GSK. The drug has faced restrictions due to Omicron variants, impacting its market share. Competitors include Paxlovid (PFE) and Lagevrio (MRK).
  • VIR-2218 (Tofersen): An investigational siRNA therapeutic in phase 2 trials for chronic hepatitis B virus (HBV) infection. Key competitors are developing novel therapeutics in the HBV space. No market share or revenue available at this stage.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high R&D spending, long development timelines, and significant regulatory oversight. It is driven by innovation and unmet medical needs.

Positioning

Vir Biotechnology is positioned as a research-driven company focused on developing innovative therapeutics for infectious diseases. Its competitive advantage lies in its proprietary antibody discovery platforms and strategic partnerships.

Total Addressable Market (TAM)

The TAM for infectious disease therapeutics is substantial and growing, driven by emerging pathogens and the increasing prevalence of chronic infections. Vir is targeting specific segments within this large TAM, such as COVID-19 and HBV.

Upturn SWOT Analysis

Strengths

  • Proprietary antibody discovery platform
  • Strategic partnerships with major pharmaceutical companies (e.g., GSK)
  • Focus on high-need infectious diseases
  • Experienced leadership team

Weaknesses

  • Reliance on partnerships for commercialization
  • Dependence on success of clinical trials
  • Fluctuating revenue based on COVID-19 treatment demand
  • High R&D expenditure

Opportunities

  • Expansion of pipeline through new drug discovery
  • Acquisition of complementary technologies or companies
  • Geographic expansion into emerging markets
  • Development of preventative vaccines or therapies

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Emergence of new variants or drug resistance

Competitors and Market Share

competitor logo Key Competitors

  • PFE
  • MRK
  • GILD
  • ABBV

Competitive Landscape

Vir's advantages include its innovative antibody discovery platform and focus on specific infectious diseases. Its disadvantages include its smaller size and limited commercial infrastructure compared to larger pharmaceutical companies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been influenced by the demand for Sotrovimab during the COVID-19 pandemic. Growth in other areas is contingent on clinical trial outcomes and regulatory approvals.

Future Projections: Future growth is dependent on the successful development and commercialization of pipeline products. Analyst estimates vary based on clinical trial progress and market conditions.

Recent Initiatives: Recent initiatives include advancing clinical trials for VIR-2218 and exploring new partnerships for drug development and commercialization.

Summary

Vir Biotechnology is a promising company focused on infectious disease therapeutics, with a strong antibody discovery platform. Its past success was influenced by COVID-19 treatments, but future growth depends on its pipeline and partnerships. Clinical trial outcomes and competition from larger firms pose challenges.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports (Publicly Available)
  • Industry News

Disclaimers:

The analysis provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Vir Biotechnology Inc

Exchange NASDAQ
Headquaters San Francisco, CA, United States
IPO Launch date 2019-10-11
CEO & Director Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 408
Full time employees 408

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.